Literature DB >> 3456562

Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae.

D S Silberstein, J R David.   

Abstract

Tumor necrosis factor (TNF) is a monocyte product that kills or inhibits the growth of certain tumor cells. Its cell source and physical characteristics suggest that it is similar to a monokine, eosinophil-cytotoxicity-enhancing factor (M-ECEF), that activates human eosinophil toxicity to Schistosoma mansoni larvae. The availability of recombinant human TNF allowed us to test this possibility. The data show that TNF has no direct effect on the parasites but enhances eosinophil toxicity to the parasites in a dose-dependent fashion. This effect is specific for eosinophils and not neutrophils. TNF and the eosinophil-specific activity of TNF are coeluted with M-ECEF in reversed-phase HPLC. Further, M-ECEF activity in HPLC fractions is reduced by treatment with rabbit anti-TNF antibody and protein A-Sepharose. This demonstrates physical similarity and at least partial immunological identity of TNF and a fraction of M-ECEF. Thus, TNF can enhance eosinophil function and may constitute an important immunological regulatory mechanism. This effect should be considered when TNF is applied clinically.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3456562      PMCID: PMC323009          DOI: 10.1073/pnas.83.4.1055

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  Colony stimulating and inhibiting activities in mouse serum after Corynebacterium parvum-endotoxin treatment.

Authors:  R G Shah; S Green; M A Moore
Journal:  J Reticuloendothel Soc       Date:  1978-01

Review 2.  Induction and immunological properties of tumor necrosis factor.

Authors:  M K Hoffmann; H F Oettgen; L J Old; R S Mittler; U Hammerling
Journal:  J Reticuloendothel Soc       Date:  1978-04

3.  A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni.

Authors:  M A Vadas; J R David; A Butterworth; N T Pisani; T A Siongok
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

4.  Killing of schistosomula of Schistosoma mansoni coated with antibody and/or complement by human leukocytes in vitro: requirement for complement in preferential killing by eosinophils.

Authors:  A R Anwar; S R Smithers; A B Kay
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

5.  Host defense mechanisms against Trichinella spiralis infection in the mouse: eosinophil-mediated destruction of newborn larvae in vitro.

Authors:  J W Kazura; M Aikawa
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

6.  Cytotoxic properties of the eosinophil major basic protein.

Authors:  G J Gleich; E Frigas; D A Loegering; D L Wassom; D Steinmuller
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

7.  Eosinophil-dependent cytotoxicity in rat schistosomiasis. Involvement of IgG2a antibody and role of mast cells.

Authors:  M Capron; A Capron; G Torpier; H Bazin; D Bout; M Joseph
Journal:  Eur J Immunol       Date:  1978-02       Impact factor: 5.532

8.  Neurotoxicity of human eosinophils.

Authors:  D T Durack; S M Sumi; S J Klebanoff
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

9.  A morphological study of the interaction between Trypanosoma cruzi and rat eosinophils, neutrophils and macrophages in vitro.

Authors:  C J Sanderson; W de Souza
Journal:  J Cell Sci       Date:  1979-06       Impact factor: 5.285

10.  Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties.

Authors:  N Matthews; J F Watkins
Journal:  Br J Cancer       Date:  1978-08       Impact factor: 7.640

View more
  41 in total

1.  Participation of eosinophils in the toxic oil syndrome.

Authors:  R M Ten; G M Kephart; M Posada; I Abaitua; L Soldevilla; E M Kilbourne; S L Dunnette; G J Gleich
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Recombinant human tumour necrosis factor (rTNF)2 enhances leukotriene biosynthesis in neutrophils and eosinophils stimulated with the Ca2+ ionophore A23187.

Authors:  R Roubin; P P Elsas; W Fiers; A J Dessein
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

3.  Tumor necrosis factor expression in human epithelial tumor cell lines.

Authors:  D R Spriggs; K Imamura; C Rodriguez; E Sariban; D W Kufe
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

4.  Identification of C3 beta chain as the human serum eosinophil cytotoxicity inhibitor.

Authors:  M S Minkoff; W W Wong; D S Silberstein
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

5.  A serum factor that suppresses the cytotoxic function of cytokine-stimulated human eosinophils.

Authors:  D S Silberstein; M S Minkoff; A A Creasey; J R David
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

Review 6.  Colony-stimulating factors in the pathogenesis and treatment of disease.

Authors:  D J Williamson; C G Begley
Journal:  Postgrad Med J       Date:  1987-12       Impact factor: 2.401

7.  Human tumor necrosis factor increases the resistance against Listeria infection in mice.

Authors:  K Kato; A Nakane; T Minagawa; N Kasai; K Yamamoto; N Sato; N Tsuruoka
Journal:  Med Microbiol Immunol       Date:  1989       Impact factor: 3.402

8.  Presence of tumour necrosis factor or a related factor in human basophil/mast cells.

Authors:  M Steffen; M Abboud; G K Potter; Y P Yung; M A Moore
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

9.  Recombinant tumour necrosis factor inhibits malaria parasites in vivo but not in vitro.

Authors:  J Taverne; J Tavernier; W Fiers; J H Playfair
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

10.  Alveolar macrophages in AIDS patients: increased spontaneous tumour necrosis factor-alpha production in Pneumocystis carinii pneumonia.

Authors:  V L Krishnan; A Meager; D M Mitchell; A J Pinching
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.